Medlab Middle East 2024 | Qankorey Technology Meet You in Dubai for a Medical Event
2024-01-19
Medlab Middle East
Medlab Middle East will be held at the United Arab Emirates-Dubai World Trade Centre on February 5, 2024.
Hundreds of medical laboratory manufacturers from more than 100 countries will participate in this exhibition. As an innovative enterprise in China's medical diagnosis industry, Qankorey Technology will also appear at this conference. Welcome to visit and exchange!
Medlab Middle East
Qankorey Technology will bring the world's first early risk screening kit for Alzheimer's disease-urine beta amyloid protein detection kit to Medlab Middle East exhibition!
This product provides the public with a faster and more convenient, non-invasive home self-inspection early screening tool. Through early screening, the risk population can be screened 20 years in advance, and preventive measures can be taken in advance to better cope with, overcome and overcome the intrusion of Alzheimer's disease on oneself and family members!
Booth number Z2.J05 welcome to visit the exchange!
Medlab Middle East
2024 Dubai World Trade Centre (DWTC)
United Arab Emirates
5-8 February 2024
Booth: Z2.J05
Qankorey Science and Technology Team sincerely invites you to visit and exchange!
Qankorey Technology
Founded in 2014, Qiankang Technology is a biotechnology Sino-foreign joint venture focusing on the research of key technologies for Alzheimer's disease, a global medical difficulty. It is also a national high-tech enterprise, a governing unit of the China Alzheimer's Disease Prevention and Control Association, and a Red Cross caring enterprise Wait.
Since its establishment, the company has been cooperating with the Florey Research Institute of the University of Melbourne in Australia and the AIBL organization in scientific research,Product development and layout around the whole industry chain of "prevention, screening, diagnosis and treatment" of Alzheimer's diseaseThe world's first internationally patented Alzheimer's disease early risk screening reagent based on urine detection of Aβ-urine beta amyloid protein detection kit has been successfully launched.
In the future, Qankorey Technology will continue to devote itself to the development and promotion of advanced Alzheimer's early screening products. Through scientific and technological innovation, it will provide more comprehensive and high-quality Alzheimer's solutions for patients and families around the world, focus on core technologies, integrate global resources, and continue to develop and innovate to serve public health!
RELATED INFORMATION
Domestic business consulting:86-0731-85714218
Company E-mail:yingxiao@qankorey.com
International Business Consulting:86-18874232226
Company E-mail:lisa@qankorey.com
Company address: 12F, Building 15, 188 Middle Huanbao Road, Yuhua District, Changsha, Hunan , 410116, China
Production Address: 4th Floor, Building 7, Yuhua Intelligent Manufacturing Center, No.2 Hongda Road, Tongsheng Street, Yuhua District, Changsha, Hunan , 410000, China
Public Number
Small program
Jingdong
Taobao